




PHARMACEUTICAL 2020

Neurotrophe Inc.
Rank 100 of 358





PHARMACEUTICAL 2020

Neurotrope Inc.
Rank 100 of 358

The relative strengths and weaknesses of Neurotrope Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Neurotrope Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 121% points. The greatest weakness of Neurotrope Inc. is the variable Net Income, reducing the Economic Capital Ratio by 81% points.

The company's Economic Capital Ratio, given in the ranking table, is 161%, being 125% points above the market average of 36%.

Input Variable	Value in 1000 USD
Assets, Current	17,876
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	479
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	4,232
Other Liabilities	0
Other Net Income	379
Other Revenues	0
Property and Equipment	22
Research and Development	4,541
Selling, General and Administrative Expense	6,741

Output Variable	Value in 1000 USD
Assets	17,898
Liabilities	479
Expenses	15,513
Revenues	0
Stockholders Equity	17,419
Net Income	-15,135
Comprehensive Net Income	-15,135
Economic Capital Ratio	161%